Price movement over the last 24 hours
Agilent Technologies Inc vs Xpeng Inc - ADR — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while Xpeng Inc - ADR trades at $13.23 (market cap $12.75B). The key difference: Agilent Technologies Inc is far larger — about 2.9× Xpeng Inc - ADR's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| A | XPEV | |
|---|---|---|
Market Cap | $37.04B | $12.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $28.07 |
52-Week Low | $110.24 | $12.09 |
Enterprise Value | $38.59B | $14.86B |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →